Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.

Astorgues-Xerri L, Vázquez R, Odore E, Rezai K, Kahatt C, Mackenzie S, Bekradda M, Coudé MM, Dombret H, Gardin C, Lokiec F, Raymond E, Noel K, Cvitkovic E, Herait P, Bertoni F, Riveiro ME.

Leuk Lymphoma. 2019 Jun 17:1-4. doi: 10.1080/10428194.2019.1617860. [Epub ahead of print] No abstract available.

PMID:
31204545
2.

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.

Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, Morschhauser F, Karlin L, Broussais F, Rezai K, Herait P, Kahatt C, Lokiec F, Salles G, Facon T, Palumbo A, Cunningham D, Zucca E, Thieblemont C.

Lancet Haematol. 2016 Apr;3(4):e196-204. doi: 10.1016/S2352-3026(16)00021-1. Epub 2016 Mar 18.

PMID:
27063978
3.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, Kahatt C, Quesnel B, Michallet M, Recher C, Lokiec F, Preudhomme C, Dombret H.

Lancet Haematol. 2016 Apr;3(4):e186-95. doi: 10.1016/S2352-3026(15)00247-1. Epub 2016 Mar 18.

PMID:
27063977
4.

Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.

Odore E, Lokiec F, Cvitkovic E, Bekradda M, Herait P, Bourdel F, Kahatt C, Raffoux E, Stathis A, Thieblemont C, Quesnel B, Cunningham D, Riveiro ME, Rezaï K.

Clin Pharmacokinet. 2016 Mar;55(3):397-405. doi: 10.1007/s40262-015-0327-6.

PMID:
26341814
5.

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.

Coudé MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, Raffoux E, Itzykson R, Delord M, Riveiro ME, Herait P, Baruchel A, Dombret H, Gardin C.

Oncotarget. 2015 Jul 10;6(19):17698-712.

6.

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.

Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, Rinaldi A, Testoni M, Cascione L, Ponzoni M, Mensah AA, Stathis A, Stussi G, Riveiro ME, Herait P, Inghirami G, Cvitkovic E, Zucca E, Bertoni F.

Clin Cancer Res. 2015 Apr 1;21(7):1628-38. doi: 10.1158/1078-0432.CCR-14-1561. Epub 2015 Jan 26.

7.

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.

Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F.

Ann Oncol. 2012 Jan;23(1):200-5. doi: 10.1093/annonc/mdr045. Epub 2011 Mar 22.

PMID:
21427067
8.

Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.

Eymard JC, Priou F, Zannetti A, Ravaud A, Lepillé D, Kerbrat P, Gomez P, Paule B, Genet D, Hérait P, Ecstein-Fraïssé E, Joly F.

Ann Oncol. 2007 Jun;18(6):1064-70. Epub 2007 Apr 13.

PMID:
17434899
9.

Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study.

Alexandre J, Rey E, Girre V, Grabar S, Tran A, Montheil V, Rabillon F, Dieras V, Jullien V, Hérait P, Pons G, Treluyer JM, Goldwasser F.

Ann Oncol. 2007 Jan;18(1):168-72. Epub 2006 Oct 23.

PMID:
17060489
10.

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.

Piedbois P, Serin D, Priou F, Laplaige P, Greget S, Angellier E, Teissier E, Berdah JF, Fabbro M, Valenza B, Herait P, Jehl V, Buyse M.

Ann Oncol. 2007 Jan;18(1):52-7. Epub 2006 Oct 17.

PMID:
17047001
11.

Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.

Cals L, Rixe O, François E, Favre R, Merad L, Deplanque G, Laadem A, Juin P, Bereder JM, Bernardini D, Herait P.

Ann Oncol. 2004 Jul;15(7):1018-24.

PMID:
15205194
12.

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.

Keating MJ, Cazin B, Coutré S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjønnfjord G, Bekradda M, Itzhaki M, Hérait P.

J Clin Oncol. 2002 Jan 1;20(1):205-13.

PMID:
11773171
13.
14.

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, Punt CJ, Alexopoulos CG, Dirix L, Symann M, Blijham GH, Cholet P, Fillet G, Van Groeningen C, Vannetzel JM, Levi F, Panagos G, Unger C, Wils J, Cote C, Blanc C, Hérait P, Bleiberg H.

Eur J Cancer. 1999 Jan;35(1):54-9.

PMID:
10211088
15.

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P.

Lancet. 1998 Oct 31;352(9138):1413-8.

PMID:
9807987
16.

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C.

Lancet. 1998 Oct 31;352(9138):1407-12. Erratum in: Lancet 1998 Nov 14;352(9140):1634.

PMID:
9807986
17.

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.

Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay M, Herait P, Cote C, Mahjoubi M, Mignard D, Cvitkovic E.

J Clin Oncol. 1998 Aug;16(8):2745-51.

PMID:
9704727
18.

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.

Merrouche Y, Extra JM, Abigerges D, Bugat R, Catimel G, Suc E, Marty M, Hérait P, Mahjoubi M, Armand JP.

J Clin Oncol. 1997 Mar;15(3):1080-6.

PMID:
9060548
19.

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M.

J Clin Oncol. 1997 Jan;15(1):251-60.

PMID:
8996150
20.

Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.

Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A.

J Clin Oncol. 1996 Oct;14(10):2688-95.

PMID:
8874328
21.

CPT-11 (irinotecan) in the treatment of colorectal cancer.

Armand JP, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G, Herait P, de Forni M, Rougier P.

Eur J Cancer. 1995 Jul-Aug;31A(7-8):1283-7. Review.

PMID:
7577037
22.

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.

Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Hérait P, Armand JP, Bugat R, et al.

Ann Oncol. 1995 Feb;6(2):141-51.

PMID:
7786822
23.

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.

Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D.

J Clin Oncol. 1995 Jan;13(1):210-21.

PMID:
7799022
24.

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.

Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Hérait P, Gandia D.

J Natl Cancer Inst. 1994 Mar 16;86(6):446-9.

PMID:
8120919
25.

Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicin in patients with advanced hepatic metastases.

Munck JN, Rougier P, Chabot GG, Ramirez LH, Bognel C, Lumbroso J, Herait P, Elias D, Lasser P, Gouyette A.

Eur J Cancer. 1994;30A(3):289-94.

PMID:
8204346
26.

Phase II trial of pirarubicin in the treatment of advanced pancreatic cancer.

Mahjoubi M, Rougier P, Oliviera J, Herait P, Tigaud JM, Droz JP.

Cancer Invest. 1994;12(4):403-5.

PMID:
8032961
27.

Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model.

Munck JN, Riggi M, Rougier P, Chabot GG, Ramirez LH, Zhao Z, Bognel C, Ardouin P, Herait P, Gouyette A.

Cancer Res. 1993 Apr 1;53(7):1550-4.

28.

CPT-11-induced cholinergic effects in cancer patients.

Gandia D, Abigerges D, Armand JP, Chabot G, Da Costa L, De Forni M, Mathieu-Boue A, Herait P.

J Clin Oncol. 1993 Jan;11(1):196-7. No abstract available.

PMID:
8418235
29.

Phase II trial of pirarubicin in the treatment of advanced bladder cancer.

Mahjoubi M, Kattan J, Ghosn M, Droz JP, Philippot I, Herait P.

Invest New Drugs. 1992 Nov;10(4):317-21.

PMID:
1487407
30.

Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer.

Chevallier B, Mignot L, Delozier T, Morvan F, Ferme C, Herait P.

Am J Clin Oncol. 1992 Oct;15(5):395-8.

PMID:
1524040
31.

Phase II trial of pirarubicin in epidermoid carcinoma of the head and neck.

Cappelaere P, Guiochet N, Chauvergne J, Bastit P, Armand JP, Lentz MA, Van Glabbeke M, Herait P, Fumoleau P.

Eur J Cancer. 1992;28(2-3):484-5. No abstract available.

PMID:
1591069
32.
33.

A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.

Robert J, Monnier A, Poutignat N, Hérait P.

Cancer Chemother Pharmacol. 1991;29(1):75-9.

PMID:
1742853
34.

[Effect and role of anthracyclines in the treatment of metastatic breast cancers].

Herait P.

Pathol Biol (Paris). 1990 Oct;38(8):859. French. No abstract available.

PMID:
2274390
35.

[THP-adriamycin: status of the clinical development of a new anthracycline in France].

Herait P.

Pathol Biol (Paris). 1990 Jan;38(1):64-8. French.

PMID:
2308782
36.

Association of bolus tetrahydropyranyl adriamycin and 120 hours continuous 5-fluorouracil infusion in patients with metastatic breast cancer.

Chevallier B, Fumoleau P, Kerbrat P, Monnier A, Roche H, Goudie MJ, Herait P.

Am J Clin Oncol. 1990;13 Suppl 1:S40-3.

PMID:
2291456
37.

Intra-arterial hepatic chemotherapy with pirarubicin. Preclinical and clinical studies.

Rougier P, Munck JN, Elias D, Herait P, Bognel C, Gosse C, Lasser P.

Am J Clin Oncol. 1990;13 Suppl 1:S1-4.

PMID:
2291452
38.

Phase II study of pirarubicin in advanced non-small cell lung cancer.

Berthaud P, Le Chevalier T, Berille J, Herait P, Baldeyrou P, Tursz T, Arriagada R, Spielmann M, Hayat M.

Eur J Cancer Clin Oncol. 1989 Oct;25(10):1507-8. No abstract available.

PMID:
2556281
39.

Phase II study of pirarubicin in advanced non-small cell lung cancer.

Berthaud P, Le Chevalier T, Berille J, Herait P, Baldeyrou P, Tursz T, Arriagada R, Spielmann M, Hayat M.

Eur J Cancer Clin Oncol. 1989 Sep;25(9):1337-8. No abstract available.

PMID:
2553419
40.
41.

Lymph node interdigitating cell granuloma associated with non-Hodgkin's malignant lymphoma. A case report and review of the literature.

Szekeres G, Le Tourneau A, Audouin J, Aubert JP, Herait P, Culine S, Zittoun R, Diebold J.

Appl Pathol. 1989;7(6):382-93. Review.

PMID:
2701267
42.

Phase II study of mitozolomide (M & B 39,565) in head and neck cancer.

Herait P, Armand JP, Benahmed M, Domenge C, Fontana X, Recondo G, Cvitkovic E, Delgado FM.

Med Oncol Tumor Pharmacother. 1989;6(4):267-9.

PMID:
2615530
43.

Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study.

Herait P, Rougier P, Theodore C, Kac JL, Droz JP.

Oncology. 1989;46(2):88-90.

PMID:
2496369
44.

Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer.

Herait P, Rougier P, Oliveira J, Delgado FM, May-Levin F, Hayat M, Armand JP.

Invest New Drugs. 1988 Dec;6(4):323-5.

PMID:
3229944
45.

Phase II trial of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinoma.

Rougier P, Droz JP, Theodore C, Piot G, Herait P, Ruffie P, Carde P, Cvitkovic E.

Cancer Treat Rep. 1987 Dec;71(12):1301-2. No abstract available.

PMID:
3690544
46.

Lymphocyte subsets in tumour of patients with undifferentiated nasopharyngeal carcinoma: presence of lymphocytes with the phenotype of activated T cells.

Herait P, Ganem G, Lipinski M, Carlu C, Micheau C, Schwaab G, De-The G, Tursz T.

Br J Cancer. 1987 Feb;55(2):135-9.

47.

[Transformation of malignant non-Hodgkin's lymphomas from low- to high-grade malignancy].

Herait P, Audouin J, Rio B, Zylberait D, Marie JP, Diebold J, Zittoun R.

Ann Med Interne (Paris). 1986;137(4):342-5. French.

PMID:
3777743
48.

Associated chronic lymphocytic leukemia and multiple myeloma: origin from a single clone.

Fermand JP, James JM, Herait P, Brouet JC.

Blood. 1985 Aug;66(2):291-3.

49.

[Sternal puncture with a fine needle. An effective and not very painful technic].

Herait P, Brilhante D, Gilles E, Cadiou M, Blanc CM, Rio B, Zittoun R.

Presse Med. 1985 Mar 2;14(9):550. French. No abstract available.

PMID:
3157178
50.

[Non-Hodgkin lymphoma arising in a case of Waldmann's intestinal lymphangiectasis].

Herait P, Gisselbrecht C, Ferme C, Jian R, Modigliani R, Griscelli C, Hervio P, Marty M, Boiron M.

Nouv Rev Fr Hematol. 1985;27(5):299-302. French.

PMID:
4080538

Supplemental Content

Loading ...
Support Center